Please login to the form below

Not currently logged in
Email:
Password:

Tyverb

This page shows the latest Tyverb news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s first-in-class breast cancer therapy wins EU licence

Pfizer’s first-in-class breast cancer therapy wins EU licence

A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),

Latest news

More from news
Approximately 3 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics